Immune Checkpoint Inhibitor-Based Immunotherapy in Cancer: Predictive Biomarkers and Mechanisms of Resistance

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 2050

Special Issue Editor

E-Mail Website
Guest Editor
EA4340-BCOH, Biomarker in Cancerology and Onco-Haematology, Université de Versailles-Saint-Quentin-En-Yvelines, Université Paris Saclay, 92100 Boulogne-Billancourt, France
Interests: immunotherapy; immunology; cancer and cell biology; targeted therapies; biomarkers; developmental pathways
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The use of immune checkpoint inhibitors (ICIs) including anti-PDL-1/PD-1 (Pembroluzimab, nivolumab, atezolizumab, avelumab, durvalumab), and anti-CTL4 (Ipilimumab), has shown promising results in various types of refractory solid and hematological malignancies such as melanoma, lung cancers, leukemia, and lymphoma. To fully exploit the potential of ICIs and uncover why some patients are still refractory to these promising drugs, studies are implemented to understand the molecular and cellular mechanisms related to ICI resistance or efficacy.

This Special Issue aims to address the latest findings related to the use of ICI-based immunotherapy in cancer, including treatment schedule, mechanisms of ICIs resistance, and predictive biomarkers.

Submissions of original articles, systematic reviews, short communications, and other types of articles on related topics are welcome. All manuscripts will follow the standard journal peer review practices, and those accepted for publication will appear in this Special Issue on “Immune-Checkpoints-Based Immunotherapy in Cancer: Predictive Biomarkers and Mechanisms of Resistance”. We look forward to receiving your contributions.

You may choose our Joint Special Issue in Vaccines.

Dr. Paul Takam Kamga
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer
  • immunotherapy
  • ICIs
  • immuno-resistance
  • predictive biomarkers

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:


Jump to: Research

5 pages, 220 KiB  
Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
by Giada Dal Collo and Paul Takam Kamga
Cancers 2023, 15(18), 4503; - 10 Sep 2023
Cited by 1 | Viewed by 1052
Immune checkpoint inhibitors (ICIs) are pharmaceutical agents capable of disrupting immune checkpoint signaling, leading to T-cell activation and a robust anti-tumor response [...] Full article


Jump to: Editorial

20 pages, 2892 KiB  
Immune and Microbial Signatures Associated with PD-1 Blockade Sensitivity in a Preclinical Model for HPV+ Oropharyngeal Cancer
by Jennifer Díaz-Rivera, Michael A. Rodríguez-Rivera, Natalie M. Meléndez-Vázquez, Filipa Godoy-Vitorino and Stephanie M. Dorta-Estremera
Cancers 2024, 16(11), 2065; - 30 May 2024
Viewed by 584
The United States is suffering from an epidemic associated with high-risk strains of the Human Papillomavirus (HPV) predominantly responsible for the development of head and neck squamous cell carcinoma (HNSCC). Treatment with immune checkpoint inhibitors targeting programmed death 1 (PD-1) or its ligand [...] Read more.
The United States is suffering from an epidemic associated with high-risk strains of the Human Papillomavirus (HPV) predominantly responsible for the development of head and neck squamous cell carcinoma (HNSCC). Treatment with immune checkpoint inhibitors targeting programmed death 1 (PD-1) or its ligand PD-L1 has shown poor efficacy in HNSCC patients, observing only a 20–30% response. Therefore, biological marker identification associated with PD-1 blockade response is important to improve prognosis and define novel therapeutics for HNSCC patients. Therapy response was associated with increased frequencies of activated CD27+T cells, activated CD79a+ B cells, antigen-presenting CD74+ dendritic and B cells, and PD-L1+ and PD-L2+ myeloid-derived suppressor cells (MDSCs). The oral microbiota composition differed significantly in mice bearing tongue tumors and treated with anti-PD-1. A higher abundance of Allobaculum, Blautia, Faecalibacterium, Dorea, or Roseburia was associated with response to the therapy. However, an increase in Enterococcus was attributed to tongue tumor-bearing non-responding mice. Our findings indicate that differences in immune phenotypes, protein expression, and bacterial abundance occur as mice develop tongue tumors and are treated with anti-PD-1. These results may have a clinical impact as specific bacteria and immune phenotype could serve as biomarkers for treatment response in HNSCC. Full article
Show Figures

Figure 1

Back to TopTop